Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis
Phase 4
Completed
- Conditions
- Atopic Dermatitis
- Registration Number
- NCT00150059
- Lead Sponsor
- Novartis
- Brief Summary
To evaluate the efficacy and safety of pimecrolimus cream 1% in its registered indication (treatment of patients \> 3 months of age with mild to moderate atopic dermatitis)
This study is not enrolling patients in the United States.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Investigator Global Assessment (IGA) score for the whole body and for the face only. Pruritus (itch) severity assessments, and patient's self-assessment of disease control at the start of study and on day 7, 30 and 90 after treatment initiation. Safety assessed by adverse events.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
This study is not being conducted in the United States
🇵🇭Investigative Site, Philippines